SCHEMBL6355252

SCHEMBL6355252

O=C(NCc1c(Cl)cccc1OCc1ccccc1)c1cccc(Cl)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGMS2 Q8NHU3 3/20 0.61
LMNA P02545 4/20 0.55
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
KMT2A Q03164 3/20 0.55
HPGD P15428 2/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
MEN1 O00255 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
ALDH1A1 P00352 3/20 0.54
TMEM97 Q5BJF2 2/20 0.49
SIGMAR1 Q99720 2/20 0.49
MRGPRX4 Q96LA9 1/20 0.48
HTT P42858 1/20 0.47
GFER P55789 1/20 0.47
TP53 P04637 1/20 0.47
GPR139 Q6DWJ6 1/20 0.46
CHRM4 P08173 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357846 0.88 SGMS2 (0.61) SGMS2LMNAMAPTL3MBTL1KMT2A
SCHEMBL6354490 0.84 LMNA (0.74) LMNAMAPTL3MBTL1KMT2AHPGD
SCHEMBL6362198 0.84 MAPT (0.65) SGMS2LMNAMAPTL3MBTL1KMT2A
SCHEMBL6356922 0.82 LMNA (0.57) SGMS2LMNAMAPTL3MBTL1KMT2A
SCHEMBL6356674 0.82 KMT2A (0.57) SGMS2LMNAMAPTL3MBTL1KMT2A
SCHEMBL6354409 0.82 NPC1 (0.56) SGMS2LMNAMAPTL3MBTL1KMT2A
SCHEMBL6357279 0.81 HPGD (0.63) LMNAMAPTKMT2AHPGDALDH1A1
SCHEMBL6355643 0.80 HPGD (0.54) SGMS2LMNAMAPTL3MBTL1KMT2A
SCHEMBL6355280 0.79 LMNA (0.55) SGMS2LMNAMAPTKMT2AHPGD
SCHEMBL6355111 0.78 ALDH1A1 (0.58) SGMS2LMNAMAPTL3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 SGMS2 3588/4885LMNA 1197/4885MAPT 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.